What Clinicians Should Know About Surrogate Endpoints in Hematologic Malignancies
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
View advanced and compelling research focused on breast cancer updates and breakthroughs as presented at ESMO Breast Cancer 2024, taking place May 15-17 in Berlin,…
Camrelizumab plus apatinib demonstrates robust and sustained efficacy in treating patients with advanced cervical cancer.
Dr. Chadi Nabhan sits down with Dr. Chandana Banerjee, a trailblazer in palliative and hospice care.
Molecular MRD after induction chemotherapy identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Patients achieving M
Pooja Desai, PhD, of AstraZeneca explains why she’s glad to be attending the 2024 National Kidney Foundation Spring Clinical Meetings.
“There are NO comparables [sic], nothing so far-reaching in its effects on politics, society, royalty, finance,” according to the auctioneer.
Date: May 22nd (Wednesday) Time: 3 pm Pacific / 6 pm Eastern Where: Online Program GVHD is a potentially life-threatening condition affecting an estimated 50%…
Supportive Care and Treatment Related Issues
Lung Cancers Today provides the latest research and clinical guidance updates on small cell and non-small cell lung cancer, mesothelioma, lung adenocarcinoma, and more.
A study found sex differences in high-risk cytogenetics among patients with myeloma, though these differences did not carry over to clinical outcomes.